Oligonucleotide Therapeutics and Delivery

[partimefriend]

Oligonucleotide Therapeutics and Delivery
4 April, 2016 - 5 April, 2016
Hyatt Regency, Cambridge, MA, USA

ANTIVIRAL DEVELOPMENT


9:00 Using DPC Technology in RNAi Therapeutics for Chronic HBV Infection and Factor 12-Mediated Diseases
David Lewis, Ph.D., CSO, Arrowhead Research Corporation

www.giiconference.com/chi338947/

www.giievent.jp/chi338947/catalog.pdf

[partimefriend]

Thought I would give this a bump, a week from this tuesday. Could see a pr this week. 

[qbeing1010]

Think we might hear something new? Like what? Very exciting times.

[partimefriend]

Hello Qb, yeah don't know of anything new really. I have been following Arwr for only a few months now, and they seem to PR the conferences they present at. Just thought we could see somthing about the Oligonucleotide Therapeutics and Delivery conference.

[wayne14072]

Anyone able to find information on what was presented today? I could not find anything posted or links from today's presentations.

[qbeing1010]

Still no news on this?

[wayne14072]

I am trying to identify if Mauro Ferrari is using DPC technology in his cancer research.  


Ferrari’s team developed porous silicon particles as drug carriers, able to travel unimpeded through healthy blood vessels thanks to their small size and disc-like shape. At the tumor site, the silicon breaks down, generating the cancer-killing nanoparticles. The nanoparticles, coiled into tiny balls that resemble cancer cells, are absorbed and taken to the cancer nucleus, where the drug is released.



The particles encase doxorubicin, a potent chemotherapy that, used conventionally, prevents tumor cells from dividing but causes adverse effects in the heart. No approach in humans has been able to deliver it only to the tumor, a limitation to the drug’s effectiveness and safety.



The strategy benefitted not just the 50 percent of mice who were disease-free eight months later, but also the half that didn’t respond as well. They lived an average of 160 days, the human equivalent of three to six years longer in humans than metastatic breast cancer patients on standard chemotherapy. The study involved triple-negative breast cancer, a hard-to-treat variety that doesn’t respond to strategies that effectively target the more common types.

Link to article:  www.expressnews.com/news/local/article/Nanotechnology-once-again-defeats-killer-cancer-6904612.php


“If this bears out in the clinic, even in a small fraction of what we’ve seen in lab experiments, it will be transformational, the first-ever demonstration of a cure of metastatic disease to the lungs,” said Mauro Ferrari, president and CEO of the Houston Methodist Research Institute and the study’s principal investigator.

The wording and timing of information coming from our company and progress being made simultaneously by Dr. Ferrari can not be coincidental.  

Also, was CLRX101 in companies portfolio with work being done with Calonado?  I do not remember the correct name of company which got divested from ARWR portfolio.  Is there also a link with CERU work? 

Any thoughts. 

[mudbug021]

The company you are referring too is Calando Pharmaceuticals

[partimefriend]

Apr 5, 2016 23:06:51 GMT -5 wayne14072 said:

Anyone able to find information on what was presented today? I could not find anything posted or links from today's presentations.

Hello Wayne, I have not been able to find any information on this conference. I think it could have been changed, the pdf shows ContraVir Pharmaceuticals Inc. in the 9:00am time slot on Tues April 5.  The web site shows Arrowhead in the same time slot.